Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Zacks.com on MSN3d
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates ViewModerna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
MT Newswires on MSN3d
Moderna Gets Third-Quarter Boost From Early COVID-19 Shot Approval as Sales Top Street ViewsModerna (MRNA) got a boost in the third quarter from an earlier US approval of its updated COVID-19 vaccine, underpinning sales growth and helping drive a surprise net income result at the drugmaker.
Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...
Moderna is also facing a lawsuit from GlaxoSmithKline (NYSE:GSK) over alleged patent infringement related to its COVID-19 vaccine, Spikevax. On the brighter side, the FDA approved Moderna's updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback